Pharmaceutical Executive-09-17-2008

News Analysis
Pharmaceutical Executive

September 17, 2008

Glaxo's cancer departments will be consolidated into one big division encompassing discovery, research, and trials. The move is expected to cost some jobs, but GSK hopes it will strengthen synergy within its R&D unit.

News Analysis
Pharmaceutical Executive

September 17, 2008

A new study from the NIMH shows that next-generation treatments for schizophrenia might not be any better than older, first generation drugs-and in some cases might be worst.